Cargando…
Allergen-Immuntherapie: Facts und FAQs
Allergen immunotherapy (AIT) is—when allergen avoidance is not sufficient—the only causative therapy of IgE-mediated allergies against aeroallergenes and Hymenoptera venoms. Allergens can be administered by either subcutaneous injection (SCIT) or sublingual application (SLIT); furthermore, oral immu...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Medizin
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8369327/ https://www.ncbi.nlm.nih.gov/pubmed/34402919 http://dx.doi.org/10.1007/s00105-021-04872-8 |
_version_ | 1783739270165430272 |
---|---|
author | Mortasawi, V. Pfützner, W. |
author_facet | Mortasawi, V. Pfützner, W. |
author_sort | Mortasawi, V. |
collection | PubMed |
description | Allergen immunotherapy (AIT) is—when allergen avoidance is not sufficient—the only causative therapy of IgE-mediated allergies against aeroallergenes and Hymenoptera venoms. Allergens can be administered by either subcutaneous injection (SCIT) or sublingual application (SLIT); furthermore, oral immunotherapy in food allergy was also recently approved. Besides correct indication (positive history and diagnostics of IgE-mediated allergy, insufficient allergen avoidance) particular attention has to be payed to potential contraindications and risks. Furthermore, unwanted side effects, which may be life-threatening, can occur. In the following, frequently asked questions (FAQs) and facts in regard to the decision-making process for the implementation as well as the risk management of AIT are discussed. |
format | Online Article Text |
id | pubmed-8369327 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Medizin |
record_format | MEDLINE/PubMed |
spelling | pubmed-83693272021-08-17 Allergen-Immuntherapie: Facts und FAQs Mortasawi, V. Pfützner, W. Hautarzt Leitthema Allergen immunotherapy (AIT) is—when allergen avoidance is not sufficient—the only causative therapy of IgE-mediated allergies against aeroallergenes and Hymenoptera venoms. Allergens can be administered by either subcutaneous injection (SCIT) or sublingual application (SLIT); furthermore, oral immunotherapy in food allergy was also recently approved. Besides correct indication (positive history and diagnostics of IgE-mediated allergy, insufficient allergen avoidance) particular attention has to be payed to potential contraindications and risks. Furthermore, unwanted side effects, which may be life-threatening, can occur. In the following, frequently asked questions (FAQs) and facts in regard to the decision-making process for the implementation as well as the risk management of AIT are discussed. Springer Medizin 2021-08-17 2021 /pmc/articles/PMC8369327/ /pubmed/34402919 http://dx.doi.org/10.1007/s00105-021-04872-8 Text en © Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Leitthema Mortasawi, V. Pfützner, W. Allergen-Immuntherapie: Facts und FAQs |
title | Allergen-Immuntherapie: Facts und FAQs |
title_full | Allergen-Immuntherapie: Facts und FAQs |
title_fullStr | Allergen-Immuntherapie: Facts und FAQs |
title_full_unstemmed | Allergen-Immuntherapie: Facts und FAQs |
title_short | Allergen-Immuntherapie: Facts und FAQs |
title_sort | allergen-immuntherapie: facts und faqs |
topic | Leitthema |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8369327/ https://www.ncbi.nlm.nih.gov/pubmed/34402919 http://dx.doi.org/10.1007/s00105-021-04872-8 |
work_keys_str_mv | AT mortasawiv allergenimmuntherapiefactsundfaqs AT pfutznerw allergenimmuntherapiefactsundfaqs |